Clovis Oncology Could Pass $100 By Year-End: Here's Why
August 07, 2015 at 10:08 AM EDT
In a report published Friday, Mizuho Securities analyst Peter Lawson maintained a Buy rating on Clovis Oncology Inc (NASDAQ: CLVS), with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.